SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : ICOS Corporation -- Ignore unavailable to you. Want to Upgrade?

To: Edscharp who wrote (731)6/24/1999 9:30:00 PM
From: Lel H  Read Replies (2) | Respond to of 1139
 
I hate to say it, but I'm pretty sure that ICOS's recent strength is going to be short-lived. The MS results should be forthcoming, and I expect that the trial will show no benefit, just like the earlier single-dose study. I suppose that one could argue that since this indication wasn't as highly regarded as shock, the effect on stock price will be muted. But bad news is bad news, and should the MS trial fail, ICOS will almost certainly take a hit.


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News